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Abstract Electronic nose (e-nose) technology has the
potential to detect cancer at an early stage and can differ-
entiate between cancer origins. Our objective was to
compare patients who had head and neck squamous cell
carcinoma (HNSCC) with patients who had colon or
bladder cancer to determine the distinctive diagnostic
characteristics of the e-nose. Feasibility study An e-nose
device was used to collect samples of exhaled breath from
patients who had HNSCC and those who had bladder or
colon cancer, after which the samples were analyzed and
compared. One hundred patients with HNSCC, 40 patients
with bladder cancer, and 28 patients with colon cancer
exhaled through an e-nose for 5 min. An artificial neural
network was used for the analysis, and double cross-vali-
dation to validate the model. In differentiating HNSCC
from colon cancer, a diagnostic accuracy of 81 % was
found. When comparing HNSCC with bladder cancer, the
diagnostic accuracy was 84 %. A diagnostic accuracy of
84 % was found between bladder cancer and colon cancer.
The e-nose technique using double cross-validation is able
to discriminate between HNSCC and colon cancer and
between HNSCC and bladder cancer. Furthermore, the
e-nose technique can distinguish colon cancer from bladder
cancer.
Keywords Electronic nose technology  Head and neck
cancer  Colon cancer  Bladder cancer  Volatile organic
compounds  Diagnosis
Introduction
The leading cause of death worldwide is cancer, with about
14.1 million new cases and 8.2 million deaths in 2012 [1].
The number of new cases is expected to rise to 22 million
within the next two decades [2]. Only early detection and
treatment can reduce the mortality rate [3]. That requires a
quick, reliable, non-invasive, and inexpensive way to
screen for cancer so that treatment might start at the earliest
possible stage of the disease. Early diagnosis could lead to
better radical treatment, less loss of function, and a higher
survival rate.
Exhaled human breath contains hundreds of volatile
organic compounds (VOCs) that can be detected by gas
chromatography and mass spectrometry (GC–MS) on the
compound level and by pattern recognition with electronic
nose (e-nose) technology. There are three types of exhaled
VOCs. Local VOCs arise directly in the alveoli or the
airway lumen along the respiratory tract. Exogenous VOCs
are ‘inhaled’ or absorbed through the skin. Some VOCs,
originating from metabolic processes in the body, dissolve
in the blood, subsequently exit the circulation and enter the
respiratory tract through the alveoli [4].
Applications of e-nose technology are common in the
food and beverage industry, in monitoring air quality, and
in the detection of explosive and chemical agents [5]. The
interaction of VOCs with an array of partial selective
chemical sensors (equivalent to the olfactory receptors in
the human nose) results in a change in the resistance or
conductance of the sensors. That change is transmitted to a
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processor. E-nose technology also has many health-care
applications; among others, it is used for diagnosing colon
cancer, chronic obstructive pulmonary disease (COPD),
asthma, lung cancer, and head and neck cancer [6–10].
Recently, van Hooren et al. 2016 reported that the e-nose
is able to discriminate between head and neck squamous cell
carcinoma (HNSCC) and lung cancer [11]. That study used a
handheld device with metal oxide sensors that are periodi-
cally heated when processing the breath sample. Oxidation
or reduction of the VOCs present in the breath sample is
measured while the resistance changes as a function of
temperature and time. Van Hooren et al. showed that e-nose
technology,which usesVOCpattern recognition, was able to
differentiate between HNSCC and lung cancer. Both types
occur in the respiratory tract and share common risk factors
such as smoking and male gender [12].
To our knowledge, no studies have been published on
the use of e-nose technology to differentiate between
HNSCC and bladder or colon cancer by means of VOC
pattern recognition. Crucially, if a tool is used to screen for
primary malignancies, it should be able to differentiate
between tumors of different types in different compart-
ments of the human body. Moreover, no other studies on
this topic have described the double cross-validation
model. That is a strategy to optimize the complexity of
regression models and make a realistic estimate of pre-
diction errors when the model is applied to new cases.
Against that backdrop, the main objective of the present
study is to determine whether the e-nose technique is able
to discriminate between HNSCC and bladder or colon
cancer using double cross-validation. The secondary
objective is to investigate whether the e-nose is able to
discriminate between colon and bladder cancer. As such,
the e-nose has potential in health care as a screening tool
for different origins of cancer.
Materials and methods
Patients
This studywas conducted in theNetherlands at a tertiary care
referral hospital (Maastricht University Medical Center). It
included patients with primary HNSCC originating from the
oral cavity, pharynx, larynx, hypopharynx, nasopharynx, or
nasal cavity. Also included were patients with primary
cancer of the bladder or colon. The study protocol was
approved by the medical ethics committee and was carried
out in accordance with the Declaration of Helsinki.
The exclusion criteria were age under 18 years, tra-
cheostomy, any treatment for current tumor, and a history
of cancer. Patients initially enrolled were subsequently
excluded when they did not or could not complete the
5-min measurement session or were unable to endure a
nose clip. Malignancies of the salivary glands were also
grounds for exclusion. The participants’ smoking habits
and metabolic fasting state were documented. The latter
was defined as no food or drink 4 h before the session,
except for two units of non-caloric clear liquid 2 h prior to
measurement. Smoking was defined as smoking in the
previous month. Tumor characteristics and medical history
were collected from the clinical records. For tumor staging,
WHO classifications were used. Carcinomas in situ and
non-invasive papillary bladder carcinomas were noted as
stage 0 tumors. Any side or adverse effects during or
shortly after measurement were documented. Informed
consent was obtained from all patients.
Study design
To acquaint the patients with the device, they received
instructions for a test run of inhalations and exhalations.
After the instructions, all patients were asked to inhale and
exhale through the e-nose for 5 min. A clipwas placed on the
nose to prevent the entry of non-filtered air. Patients were
instructed to enclose the lips by the mouthpiece at all times.
E-nose readings were synchronous with the regular
diagnostic workup. Participants were not given any diag-
nostic information derived from their individual e-nose
results. The routine diagnostic workup was based on
national cancer guidelines and was independent of e-nose
measurements. The e-nose outcomes were compared with
histopathology from biopsies.
Materials
The device used in this study (Aeonose; the eNose Com-
pany, Zutphen, the Netherlands) consists of three different
micro-hotplate metal oxide sensors (AS-MLV sensors;
Applied Sensors GmbH.). During the measurement, the
hotplates are periodically heated and cooled between 260
and 340 C in 32 steps during which the sensors are
exposed to the exhaled breath. The reduction and oxidation
(redox) reactions of the VOCs on the metal oxide surface
affect the conductivity of the sensors. Over time, these
changes create a unique pattern of redox reactions. (See
van Hooren et al. 2016 for more details on the method)
[11]. The measurements were performed with five Aeo-
noses (serial numbers 259, 309, 315, 362, and 379) to
exclude possible machine-bound confounding factors.
Statistical analysis
Differences in baseline characteristics were determined
with the independent sample t test, Fisher’s exact test, or
Pearson’s Chi square test. All statistical analyses were
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performed using IBM SPSS Statistics for Windows, Ver-
sion 22.0 (IBM Corp.; Armonk, NY, USA).
Each e-nose measurement generates 64 (temperature
values) times 36 (measurement cycles) times 3 (sensor)
data points, forming a multi-way dataset consisting of
conductivity values. After preprocessing, the data are
compressed using a TUCKER3 solution for tensor
decomposition. The vectors representing the coded patient
information are subsequently used to train an artificial
neural network (ANN). This training is carried out for a
number of data scaling options, yielding different models
for separating ‘HNSCC’ from ‘colon or bladder cancer’
patients. Data compression and ANN have been integrated
in a proprietary software package (Aethena) of the eNose
Company (Zutphen, the Netherlands). The binary results
are presented in a scatter plot and a receiver operating
characteristic curve (ROC curve). Matthews correlation
coefficients (MCC) were calculated to determine the
Table 1 TNM staging of HNSCC patients
0 CIS 1 2 3 4
T / 3 28 30 19 20
N 60 / 13 25 2 /
M 95 / 5 / / /
Table 2 Baseline characteristics of HNSCC and colon cancer
HNSCC Colon p value Test
Number of patients 100 28
Age (years) 64 69 0.0240 
Sex (male) 74 18 0.209 
Food intake\4 h (‘‘Yes’’) 23 4 0.162 
Currently smoking 57 4 0.0000 
Pack-years 34 17 0.0020 












* Pearson Chi square
 Fisher’s exact test
 Independent t test
0 Significant
Table 3 Baseline characteristics of HNSCC and bladder cancer
HNSCC Bladder p value Test
Number of patients 100 40
Age (years) 64 68 0.0200 
Sex (male) 74 28 0.555 
Food intake\4 h (‘‘Yes’’) 64 23 0.0380 
Currently smoking 57 10 0.0020 
Pack-years 37 27 0.076 












* Pearson Chi square
 Fisher’s exact test
 Independent t test
0 Significant
Table 4 Baseline characteristics of colon cancer and bladder cancer
Colon Bladder p value Test
Number of patients 28 40
Age (years) 68 69 0.535 
Sex (male) 18 30 0.246 
Food intake\4 h (‘‘Yes’’) 23 24 0.065 
Currently smoking 4 11 0.160 
Pack-years 40 28 0.106 












* Pearson Chi square
 Fisher’s exact test
 Independent t test
0 Significant
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quality of the binary classifications and 95 % confidence
intervals (CI) were given.
The data were labeled with the diagnosis of HNSCC, or
colon cancer, or bladder cancer when processed in
Aethena. The optimal results were obtained by combining
multiple ANNs in the following sequence. First, one ANN
separated all data into a positive and a negative group.
Then each group was judged by three different ANNs,
generating an average value of the ANN classifications
(judge model). To calculate sensitivity, specificity, and
overall accuracy for future, yet undefined breath samples,
double cross-validation was performed. Using brute
(computing) force, the optimal combination of available
ANNs was determined. Double cross-validation ensures
that comparable results can be expected when submitting
blind data into the trained ANN.
Results
One hundred and sixty-eight patients were included in this
study. They had histopathologically proven HNSCC
(N = 100), bladder cancer (N = 40), or colon cancer
(N = 28). The tumor sites of the HNSCC patients were the
oral cavity (N = 28), oropharynx (N = 23), nasophar-
ynx/nasal cavity (N = 4), hypopharynx (N = 11), and
larynx (N = 34). All HNSCC patients were diagnosed with
squamous cell carcinoma (including three patients with
squamous cell carcinoma in situ). In Table 1, the TNM
stadiums of all HNSSC patients are shown.
HNSCC and colon cancer
The baseline characteristics of the HNSCC vs. colon cancer
patients are listed in Table 2. There are several baseline
differences between the two groups: age (p = 0.024),
currently smoking (p = 0.000), pack-years (p = 0.002),
and tumor stage (p = 0.018). Of the 28 patients with colon














In ﬁgure 1 the individual E-nose value of each paent are ploed. Values  > 0 are scored as being posive for Colon cancer. Values  < 0 are 
scored as being posive for HNSCC . The Red dots are paents with histopathologic conﬁrmed Colon cancer and the blue dots represent 
paents with histopathologic conﬁrmed HNSCC















The ROC-curve in ﬁgure 2 illustrates the diﬀerent sensivies and speciﬁcies with altered thresholds of 
both the best ﬁt of the data for double cross-validaon (red line). The Blue line represents the ine of no-
discriminaon. The area under the curve (AUC) is 0.83 (95% CI 0.74-0.92)
Fig. 2 ROC curve of HNSCC and colon cancer
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HNSCC and bladder cancer
The baseline characteristics of the head and neck vs. bladder
cancer patients are listed in Table 3. Several baseline dif-
ferences were found: age (p = 0.020), food intake
(p = 0.038), smoking (p = 0.002), and tumor stage
(p = 0.000). There were 24 patients with a stage 0 tumor.
Four patients had a carcinoma in situ, respectively, threewith
HNSCC and one bladder cancer patient. The remaining 20
patients had non-invasive papillary bladder carcinomas.
Bladder cancer and colon cancer
Only one significant difference in baseline characteristic
was found: tumor stage (p = 0.000). The data are pre-
sented in Table 4.
Data analysis
HNSCC and colon cancer
Figure 1 is a scatter plot of individual predictive values
with a best fit of the data analyzed by the ANN. To obtain
the best possible diagnostic accuracy of the data, the
threshold was set to 0.00. This resulted in a sensitivity of
79 % and specificity of 81 %, with an overall accuracy of
81 % (MCC: 0.56) in differentiating between colon cancer
and HNSCC. Cross-validation data are shown in Fig. 2.
HNSCC and bladder cancer
Figure 3 is a scatter plot of individual predictive values
with a best fit of the data analyzed by the ANN. To obtain
the best possible diagnostic accuracy, the threshold was set
to 0.00. The sensitivity was 80 % and specificity was 86 %,
at an overall accuracy of 84 % (MCC: 0.66) in differenti-
ating between colon carcinoma and HNSCC. Cross-vali-
dation data are given in Fig. 4.
Bladder cancer and colon cancer
The scatter plot in Fig. 5 displays the individual predictive
values with a best fit of the data analyzed by the ANN. For
the best possible diagnostic accuracy, the threshold was set
to 0.00. This resulted in a sensitivity of 88 % and speci-
ficity of 79 %, and an overall accuracy of 84 % (MCC:
0.69) in differentiating between colon carcinoma and














Figure 3 shows the individual E-nose value of each paent . Values  > 0 are scored as being posive for Bladder cancer. Values < 0 are 
scored as being posive for HNSCC . The Red dots are paents with  histopathologic conﬁrmed bladder cancer and the blue dots represent 
paents with histopathologic conﬁrmed HNSCC.















1 - Speciﬁty 
The ROC-curve in ﬁgure 4 2 2 illustrates the diﬀerent sensivies and speciﬁcies with altered thresholds of 
both the best ﬁt of the data for double cross-validaon (red line). Blue line represents the ine of no-
discriminaon. The area under the curve (AUC) is 0.85 (95% CI 0,76-0,94)
Fig. 4 ROC curve of HNSCC and bladder cancer
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Discussion
In this feasibility study, the breath VOC patterns of patients
with HNSCC were compared to the patterns of patients
with colon or bladder cancer. Our results show that breath
VOC pattern analysis with the e-nose is feasible. The
technique exhibits a reasonable degree of sensitivity and
specificity for double cross-validation when comparing
HNSCC with colon cancer or bladder cancer.
Interest in the use of VOCs in diagnosing primary car-
cinomas has been growing. Meij et al. [6] tested 157 stool
samples (40 patients with colon cancer, 60 patients with
advanced adenomas, and 57 healthy controls). They found
that the VOC profiles of patients with colon cancer differed
significantly from those of controls without cancer (AUC
0.92, sensitivity 85 %, and specificity 87 %). Amel et al.
[13] evaluated the breath VOC pattern analysis by testing
65 patients with colon cancer and 122 healthy controls.
Their sensor analysis distinguished colon cancer from the
healthy control group with 85 % sensitivity, 94 % speci-
ficity, and 91 % accuracy. Comparing HNSCC patients
with healthy subjects, Gruber et al. [14] used an e-nose to
analyze the breath samples of 22 patients with malignant
larynx or pharynx tumors and 21 healthy controls. They
were able to distinguish HNSCC patients from healthy
controls as well as from individuals with benign tumors at a
sensitivity of 77 %, specificity of 90 %, and overall accu-
racy of 83 %. Our group used an e-nose to evaluate VOC
patterns in the exhaled breath of 36 HNSCC patients and
23 patients without malignant disease and found 90 %
sensitivity and 80 % specificity in diagnosing HNSCC
[10]. Using pattern recognition and principal component
analysis (PCA), Peng et al. [15] showed that an e-nose can
distinguish different tumors in different tracts (lung, colon,
breast, prostate). Against that background, the innovative
aspect of the present study is that double cross-validation is
shown to improve the diagnostic accuracy when the gen-
erated Judge model is applied to new cases. Furthermore,
this generated model can be translated to different Aeonose
devices.
Double cross-validation showed a sensitivity of 79 %
and specificity of 81 % when HNSCC was compared with
colon cancer using breath samples and the e-nose. When
comparing HSCNN with bladder cancer, this study found a
sensitivity of 80 % and specificity of 86 %, and it showed a
sensitivity of 88 % and specificity of 79 % when com-
paring bladder cancer with colon cancer.
In the past decade, diagnosis of primary cancers with
VOCs has shown promising results. Among the various













Figure 5  shows the individual E-nose value of each paent . Values  > 0 are scored as being posive for Bladder cancer. Values  <0 are scored as being 
posive for Colon cancer. The Red dots are paents with histopathologic conﬁrmed bladder cancer and the blue dots represent paents with 
histopathologic conﬁrmed Colon cancer.
Fig. 5 Scatter plot of bladder














1 - Speciﬁty 
The ROC-curve in ﬁgure 6 illustrates the diﬀerent sensivies and speciﬁcies with altered thresholds of 
both the best ﬁt of the data (blue line) as the double cross-validaon (red line). The area under the curve 
(AUC) is 0.90(95% CI 0,81-0,98)
Fig. 6 ROC curve of bladder and colon cancer
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identify specific volatile organic compounds for diseases of
interest. However, this method has some disadvantages:
cost, its time-consuming procedure, and the need for well-
trained personnel to collect and analyze the samples. Fur-
thermore, the identification of detected compounds is not
straightforward; reference libraries have to be checked and
validated using the mass and retention time of known
standards.
Another method, the one used in this study, is e-nose
technology, which is based on pattern recognition. The
e-nose needs to be ‘trained’ to build a database for
recognition, after which it can be used to classify blind
samples. The crucial factors of meaningful pattern recog-
nition are the size of the training set and representativeness
of the sample for the populations to be tested. The
advantage of the e-nose used in this study (Aeonose) is that
it is a portable handheld device, making it easily applicable
in an outpatient setting. Furthermore, the method is quick
and fairly cheap.
Limitations
The design of this feasibility study entailed some limita-
tions; therefore, some caution should be taken when
interpreting our results. First, there were significant base-
line differences in both the HNSCC vs. colon cancer
analysis and the HNSCC vs. bladder cancer analysis. These
differences reflect the clinical setting: the majority of
patients with HNSCC are smokers with an advanced tumor
stage at first presentation [16]. Second, none of the patients
with bladder or colon carcinoma had received a panen-
doscopy or any other diagnostic procedure to exclude
HNSCC, as no clinical symptoms were present at the time
of sample collection.
Conclusion
The e-nose technique, using double cross-validation, is
able to discriminate between HNSCC and colon cancer
(sensitivity 79 %, specificity 81 %) and between HNSCC
and bladder cancer (sensitivity 80 %, specificity 86 %).
Furthermore, the e-nose can distinguish colon cancer from
bladder cancer (sensitivity 88 %, specificity 79 %). Large,
preferably blinded studies should be conducted to deter-
mine the role that the e-nose could play as a diagnostic tool
in primary cancer diagnostics and management.
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